LONDON (AP) — Smoking high-potency marijuana every day could increase the chances of developing psychosis by nearly five times, according to the biggest-ever study to examine the impact of pot on psychotic disorder rates.
The research adds to previous studies that have found links between marijuana and mental health problems, but still does not definitively pinpoint marijuana as the cause.
Psychotic disorders — in which people lose touch with reality — are typically triggered by factors including genetics and the environment. But experts say the new study’s findings have implications for jurisdictions legalizing marijuana, warning they should consider the potential impact on their mental health services.
High potency cannabis linked to higher rates of psychosis
New research from King’s College London is the first to show the impact of cannabis use on population rates of psychosis, highlighting the potential public health impact of changes to cannabis… kcl.ac.uk
“If we think there’s something particular about (high-potency) cannabis, then making that harder to get a hold of, could be a useful harm-reduction measure,” said Suzanne Gage, of the University of Liverpool, who was not connected to the new study.
Researchers at King’s College London and elsewhere analyzed data from a dozen sites across Europe and Brazil from 2010 to 2015. About 900 people who were diagnosed with a first episode of the disorder at a mental health clinic, including those with delusions and hallucinations, were compared with more than 1,200 healthy patients. After surveying the patients about their use of cannabis and other drugs, researchers found daily marijuana use was more common among patients with a first episode of psychosis compared with the healthy, control group.
The scientists estimated that people who smoked marijuana on a daily basis were three times more likely to be diagnosed with psychosis compared with people who never used the drug. For those who used high-potency marijuana daily, the risk jumped to nearly five times. The paper was published online Tuesday by the journal Lancet. It was paid for by funders including Britain’s Medical Research Council, the Sao Paulo Research Foundation and the Wellcome Trust.
Published: March 20, 2019
Founder & Interim Editor of L.A. Cannabis News